High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm

Lala M. Dunbar, Richard G. Wunderink, Michael P. Habib, Leon G. Smith, Alan M. Tennenberg, Mohammed M. Khashab, Barbara A. Wiesinger, Jim X. Xiang, Neringa Zadeikis, James B. Kahn

    Research output: Contribution to journalArticlepeer-review

    299 Scopus citations


    Levofloxacin demonstrates concentration-dependent bactericidal activity most closely related to the pharmacodynamic parameters of the ratio of area under the concentration-time curve (AUC) to minimum inhibitory concentration (MIC) and the ratio of peak plasma concentration (Cmax) to MIC. Increasing the dose of levofloxacin to 750 mg exploits these parameters by increasing peak drug concentrations, allowing for a shorter course of treatment without diminishing therapeutic benefit. This was demonstrated in a multicenter, randomized, double-blind investigation that compared levofloxacin dosages of 750 mg per day for 5 days with 500 mg per day for 10 days for the treatment of mild to severe community-acquired pneumonia (CAP). In the clinically evaluable population, the clinical success rates were 92.4% (183 of 198 persons) for the 750-mg group and 91.1% (175 of 192 persons) for the 500-mg group (95% confidence interval, -7.0 to 4.4). Microbiologic eradication rates were 93.2% and 92.4% in the 750-mg and 500-mg groups, respectively. These data demonstrate that 750 mg of levofloxacin per day for 5 days is at least as effective as 500 mg per day for 10 days for treatment of mild-to-severe CAP.

    Original languageEnglish (US)
    Pages (from-to)752-760
    Number of pages9
    JournalClinical Infectious Diseases
    Issue number6
    StatePublished - Sep 15 2003

    ASJC Scopus subject areas

    • Microbiology (medical)
    • Infectious Diseases


    Dive into the research topics of 'High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm'. Together they form a unique fingerprint.

    Cite this